Web basEd soCial Media tecHnology to Improvement in Adherence to Dual anTiplatelet Therapy Following Drug-Eluting Stent Implantation

Coronary Disease Clinical Trial

— WeChat  

Official title:

Web basEd soCial Media tecHnology to Improvement in Adherence to Dual anTiplatelet Therapy Following Drug-Eluting Stent Implantation (WeChat), a Randomized Controlled Branch on Antiplatelet of RESCIND Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03732066
• Other study ID #: GDREC2018327H
• Status: Recruiting
• Phase: N/A
• Start date: January 14, 2019
• Est. completion date: September 30, 2021

Study information

• Verified date: August 2020
• Source: Guangdong Provincial People's Hospital
• Contact: Yong Liu, MD
• Phone: 86-15920172292
• Email: liuyong2099[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Few studies have attempt to improve DAPT adherence through social media. The investigators will explore the prevalence of DAPT discontinuation and prove the hypothesis that using social media will improve DAPT adherence among patients requiring DAPT following DES implantation.

Description:

Dual antiplatelet therapy (DAPT) is frequently discontinued after drug-eluting stent (DES) implantation, which could lead to many major adverse cardiovascular events (MACEs). Social media have been proven effective in improving lifestyles and blood pressures control, but few studies have attempt to improve DAPT adherence through social media.Therefore, eligible patients will be enrolled through scanning QR code and randomized in a 1:1 ratio to an intervention group or control group with 12 months of follow-up.The investigators will find out the prevalence of DAPT discontinuation and prove the hypothesis that using social media will improve DAPT adherence among patients requiring DAPT following DES implantation..

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 760
• Est. completion date: September 30, 2021
• Est. primary completion date: March 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• aged =18 years

• diagnosed CHD and underwent DES implantation

• provide written informed consent

Exclusion Criteria:

• pregnancy

• malignant tumor or end-stage disease with a life expectancy of <1 year;

• refusal to use social media

• refusal to provide written informed consent for this study

Related Conditions & MeSH terms

• Coronary Disease

Intervention

Behavioral:
• Usual Text Messages
Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
• Personalized Reminders
The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of >180 mmHg or <90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on. Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days.
• Interactive Responses
Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians. The researchers will communicate with the patients every month.

Locations

Country	Name	City	State
China	Guangdong General Hospital	Guangzhou	Guangdong

Sponsors (5)

Lead Sponsor	Collaborator
Guangdong Provincial People's Hospital	Dongguan People's Hospital, First People's Hospital, Shunde China, Guangzhou Panyu Central Hospital, Maoming General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Discontinuation of Dual Antiplatelet Drug	Defined as discontinuation of any dual antiplatelet drug owing to patients' own discretion, including bleeding or non-compliance rather than doctors' advice. Changing of DAPT medication between ticagrelor and clopidogrel under doctors' advice will not be identified as dual antiplatelet drug discontinuation; changing of such under own discretion will be identified as such	1 year
Secondary	Medication Adherence	Dual antiplatelet therapy (DAPT) adherence according to proportion of days covered (PDC) by prescription.	1 year
Secondary	Number of Participants with Major Adverse Cardiovascular Events	All-cause mortality,target vessel revascularization, non-fatal myocardial infarction, and stroke	1 year